Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has ...

On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a decline, ending the day at $59.5 which represents a decrease of $-0.19 or -0.32% from the prior close of $59.69. The stock opened at $59.66 ...

Begin your TipRanks Premium journey today. Longboard Pharmaceuticals (LBPH) Company Description: Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel ...

Longboard Pharmaceuticals, Inc. ( (LBPH) ) has released its Q3 earnings. Here is a breakdown of the information Longboard Pharmaceuticals, Inc.

(Bloomberg) -- H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases. The Danish pharmaceutical company is ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) have earned an average rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports.

In terms of valuation, Longboard Pharmaceuticals Inc’s market capitalization stands at $2.33 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a ...

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) rose sharply in today's pre-market trading. Lundbeck agreed to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...